# Tactile Systems Technology Inc: financial statements, quarterly

TCMD · Nasdaq · CIK 1027838 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/tcmd.md) · [Financials](/companies/tcmd/financials.md) · [Filings](/companies/tcmd/filings.md) · [Insiders](/companies/tcmd/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/tcmd/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [69.6](/filings/0001558370-24-014259.md) | [77.7 d](/filings/0001104659-26-016380.md) | [61.1](/filings/0001558370-25-006295.md) | [73.2](/filings/0001558370-25-010098.md) | [73.1](/filings/0001104659-25-105543.md) | [85.6 d](/filings/0001104659-26-016380.md) | [61.3](/filings/0001104659-26-054877.md) | [78.9](/filings/0001104659-26-093352.md) | [85.8](/filings/0001104659-25-105543.md) | [104 d](/filings/0001104659-26-016380.md) | [75.3](/filings/0001104659-26-054877.md) | [85.7](/filings/0001104659-26-093352.md) |
| Cost of revenue | $m | [20.2](/filings/0001558370-24-014259.md) | [21.6 d](/filings/0001104659-26-016380.md) | [17.7](/filings/0001558370-25-006295.md) | [19.1](/filings/0001558370-25-010098.md) | [18.3](/filings/0001104659-25-105543.md) | [21.2 d](/filings/0001104659-26-016380.md) | [15.9](/filings/0001104659-26-054877.md) | [20.1](/filings/0001104659-26-093352.md) | [20.8](/filings/0001104659-25-105543.md) | [22.6 d](/filings/0001104659-26-016380.md) | [17.7](/filings/0001104659-26-054877.md) | [20.3](/filings/0001104659-26-093352.md) |
| Gross profit | $m | [49.4](/filings/0001558370-24-014259.md) | [56.0 d](/filings/0001104659-26-016380.md) | [43.4](/filings/0001558370-25-006295.md) | [54.1](/filings/0001558370-25-010098.md) | [54.8](/filings/0001104659-25-105543.md) | [64.4 d](/filings/0001104659-26-016380.md) | [45.3](/filings/0001104659-26-054877.md) | [58.8](/filings/0001104659-26-093352.md) | [65.0](/filings/0001104659-25-105543.md) | [81.0 d](/filings/0001104659-26-016380.md) | [57.6](/filings/0001104659-26-054877.md) | [65.3](/filings/0001104659-26-093352.md) |
| Research and development | $m | [2.0](/filings/0001558370-24-014259.md) | [1.8 d](/filings/0001104659-26-016380.md) | [2.1](/filings/0001558370-25-006295.md) | [2.2](/filings/0001558370-25-010098.md) | [2.4](/filings/0001104659-25-105543.md) | [2.0 d](/filings/0001104659-26-016380.md) | [1.7](/filings/0001104659-26-054877.md) | [2.0](/filings/0001104659-26-093352.md) | [2.2](/filings/0001104659-25-105543.md) | [2.5 d](/filings/0001104659-26-016380.md) | [2.8](/filings/0001104659-26-054877.md) | [2.5](/filings/0001104659-26-093352.md) |
| Operating income | $m | [8.0](/filings/0001558370-24-014259.md) | [11.8 d](/filings/0001104659-26-016380.md) | [(3.0)](/filings/0001558370-25-006295.md) | [5.8](/filings/0001558370-25-010098.md) | [6.8](/filings/0001104659-25-105543.md) | [12.5 d](/filings/0001104659-26-016380.md) | [(4.5)](/filings/0001104659-26-054877.md) | [4.1](/filings/0001104659-26-093352.md) | [11.0](/filings/0001104659-25-105543.md) | [18.8 d](/filings/0001104659-26-016380.md) | [(1.5)](/filings/0001104659-26-054877.md) | [6.8](/filings/0001104659-26-093352.md) |
| Interest expense | $m | not reported | not reported | [0.6](/filings/0001558370-25-006295.md) | [0.5](/filings/0001558370-25-010098.md) | [0.5](/filings/0001104659-25-105543.md) | [0.5 d](/filings/0001104659-26-016380.md) | [0.4](/filings/0001104659-26-054877.md) | [0.4](/filings/0001104659-26-093352.md) | [0.2](/filings/0001104659-25-105543.md) | [0.0 d](/filings/0001104659-26-016380.md) | [0.0](/filings/0001104659-26-054877.md) | [0.0](/filings/0001104659-26-093352.md) |
| Income tax | $m | [(14.7)](/filings/0001558370-24-014259.md) | [3.6 d](/filings/0001104659-26-016380.md) | [(0.6)](/filings/0001558370-25-006295.md) | [1.8](/filings/0001558370-25-010098.md) | [2.1](/filings/0001104659-25-105543.md) | [3.3 d](/filings/0001104659-26-016380.md) | [(1.1)](/filings/0001104659-26-054877.md) | [1.3](/filings/0001104659-26-093352.md) | [3.2](/filings/0001104659-25-105543.md) | [8.8 d](/filings/0001104659-26-016380.md) | [0.9](/filings/0001104659-26-054877.md) | [(0.4)](/filings/0001104659-26-093352.md) |
| Net income | $m | [22.3](/filings/0001558370-24-014259.md) | [8.2 d](/filings/0001104659-26-016380.md) | [(2.2)](/filings/0001558370-25-006295.md) | [4.3](/filings/0001558370-25-010098.md) | [5.2](/filings/0001104659-25-105543.md) | [9.7 d](/filings/0001104659-26-016380.md) | [(3.0)](/filings/0001104659-26-054877.md) | [3.2](/filings/0001104659-26-093352.md) | [8.2](/filings/0001104659-25-105543.md) | [10.6 d](/filings/0001104659-26-016380.md) | [(1.8)](/filings/0001104659-26-054877.md) | [7.8](/filings/0001104659-26-093352.md) |
| Diluted EPS | $ per share | [0.94](/filings/0001558370-24-014259.md) | not reported | [(0.09)](/filings/0001558370-25-006295.md) | [0.18](/filings/0001558370-25-010098.md) | [0.21](/filings/0001104659-25-105543.md) | not reported | [(0.13)](/filings/0001104659-26-054877.md) | [0.14](/filings/0001104659-26-093352.md) | [0.36](/filings/0001104659-25-105543.md) | not reported | [(0.08)](/filings/0001104659-26-054877.md) | [0.34](/filings/0001104659-26-093352.md) |
| Basic EPS | $ per share | [0.95](/filings/0001558370-24-014259.md) | not reported | [(0.09)](/filings/0001558370-25-006295.md) | [0.18](/filings/0001558370-25-010098.md) | [0.21](/filings/0001104659-25-105543.md) | not reported | [(0.13)](/filings/0001104659-26-054877.md) | [0.14](/filings/0001104659-26-093352.md) | [0.37](/filings/0001104659-25-105543.md) | not reported | [(0.08)](/filings/0001104659-26-054877.md) | [0.34](/filings/0001104659-26-093352.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [66.0](/filings/0001558370-23-017787.md) | [61.0](/filings/0001558370-25-001096.md) | [60.7](/filings/0001558370-24-006795.md) | [73.6](/filings/0001558370-24-010856.md) | [82.1](/filings/0001558370-24-014259.md) | [94.4](/filings/0001104659-26-016380.md) | [83.6](/filings/0001558370-25-006295.md) | [81.5](/filings/0001558370-25-010098.md) | [66.0](/filings/0001104659-25-105543.md) | [83.4](/filings/0001104659-26-093352.md) | [75.0](/filings/0001104659-26-054877.md) | [69.9](/filings/0001104659-26-093352.md) |
| Current assets | $m | [152](/filings/0001558370-23-017787.md) | [145](/filings/0001558370-25-001096.md) | [141](/filings/0001558370-24-006795.md) | [152](/filings/0001558370-24-010856.md) | [162](/filings/0001558370-24-014259.md) | [178](/filings/0001104659-26-016380.md) | [160](/filings/0001558370-25-006295.md) | [153](/filings/0001558370-25-010098.md) | [141](/filings/0001104659-25-105543.md) | [165](/filings/0001104659-26-093352.md) | [153](/filings/0001104659-26-054877.md) | [158](/filings/0001104659-26-093352.md) |
| Total assets | $m | [293](/filings/0001558370-23-017787.md) | [281](/filings/0001558370-25-001096.md) | [272](/filings/0001558370-24-006795.md) | [279](/filings/0001558370-24-010856.md) | [288](/filings/0001558370-24-014259.md) | [298](/filings/0001104659-26-016380.md) | [280](/filings/0001558370-25-006295.md) | [273](/filings/0001558370-25-010098.md) | [259](/filings/0001104659-25-105543.md) | [274](/filings/0001104659-26-093352.md) | [272](/filings/0001104659-26-054877.md) | [280](/filings/0001104659-26-093352.md) |
| Current liabilities | $m | [45.6](/filings/0001558370-23-017787.md) | [41.1](/filings/0001558370-25-001096.md) | [33.1](/filings/0001558370-24-006795.md) | [34.2](/filings/0001558370-24-010856.md) | [37.2](/filings/0001558370-24-014259.md) | [40.7](/filings/0001104659-26-016380.md) | [35.4](/filings/0001558370-25-006295.md) | [40.4](/filings/0001558370-25-010098.md) | [39.2](/filings/0001104659-25-105543.md) | [41.0](/filings/0001104659-26-093352.md) | [36.0](/filings/0001104659-26-054877.md) | [38.3](/filings/0001104659-26-093352.md) |
| Total liabilities | $m | [110](/filings/0001558370-23-017787.md) | [87.8](/filings/0001558370-25-001096.md) | [78.6](/filings/0001558370-24-006795.md) | [78.1](/filings/0001558370-24-010856.md) | [79.8](/filings/0001558370-24-014259.md) | [81.3](/filings/0001104659-26-016380.md) | [74.6](/filings/0001558370-25-006295.md) | [78.1](/filings/0001558370-25-010098.md) | [54.2](/filings/0001104659-25-105543.md) | [55.0](/filings/0001104659-26-093352.md) | [54.3](/filings/0001104659-26-054877.md) | [55.8](/filings/0001104659-26-093352.md) |
| Long-term debt | $m | not reported | [16.8](/filings/0001558370-24-001330.md) | [28.5](/filings/0001558370-24-006795.md) | [27.8](/filings/0001558370-24-010856.md) | [27.0](/filings/0001558370-24-014259.md) | not reported | not reported | not reported | [0.0](/filings/0001104659-25-105543.md) | [0.0](/filings/0001104659-26-016380.md) | [0.0](/filings/0001104659-26-054877.md) | [0.0](/filings/0001104659-26-093352.md) |
| Shareholders' equity | $m | [183](/filings/0001558370-24-014259.md) | [194](/filings/0001104659-26-016380.md) | [193](/filings/0001558370-25-010098.md) | [201](/filings/0001104659-25-105543.md) | [208](/filings/0001104659-25-105543.md) | [217](/filings/0001104659-26-093352.md) | [206](/filings/0001104659-26-093352.md) | [195](/filings/0001104659-26-093352.md) | [205](/filings/0001104659-25-105543.md) | [219](/filings/0001104659-26-093352.md) | [218](/filings/0001104659-26-093352.md) | [224](/filings/0001104659-26-093352.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [4.1 d](/filings/0001558370-24-014259.md) | [18.4 d](/filings/0001104659-26-016380.md) | [0.9](/filings/0001558370-25-006295.md) | [13.1 d](/filings/0001558370-25-010098.md) | [10.3 d](/filings/0001104659-25-105543.md) | [16.3 d](/filings/0001104659-26-016380.md) | [0.4](/filings/0001104659-26-054877.md) | [14.8 d](/filings/0001104659-26-093352.md) | [10.3 d](/filings/0001104659-25-105543.md) | [17.3 d](/filings/0001104659-26-016380.md) | [(0.3)](/filings/0001104659-26-054877.md) | [3.3 d](/filings/0001104659-26-093352.md) |
| Capital expenditure | $m | [0.4 d](/filings/0001558370-24-014259.md) | [0.9 d](/filings/0001104659-26-016380.md) | [0.5](/filings/0001558370-25-006295.md) | [0.5 d](/filings/0001558370-25-010098.md) | [1.0 d](/filings/0001104659-25-105543.md) | [0.5 d](/filings/0001104659-26-016380.md) | [0.4](/filings/0001104659-26-054877.md) | [0.4 d](/filings/0001104659-26-093352.md) | [1.1 d](/filings/0001104659-25-105543.md) | [0.5 d](/filings/0001104659-26-016380.md) | [0.8](/filings/0001104659-26-054877.md) | [1.3 d](/filings/0001104659-26-093352.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | [10.0](/filings/0001104659-26-054877.md) | [16.5 d](/filings/0001104659-26-093352.md) | [0.0 d](/filings/0001104659-25-105543.md) | [(0.0) d](/filings/0001104659-26-016380.md) | [1.1](/filings/0001104659-26-054877.md) | [5.3 d](/filings/0001104659-26-093352.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [20.1](/filings/0001558370-23-017787.md) | [21.3](/filings/0001558370-24-006795.md) | [23.4](/filings/0001558370-24-010856.md) | [23.8](/filings/0001558370-24-014259.md) | [23.7](/filings/0001558370-25-006295.md) | [24.1](/filings/0001558370-25-010098.md) | [24.3](/filings/0001104659-25-105543.md) | [23.7](/filings/0001104659-26-054877.md) | [23.2](/filings/0001104659-26-093352.md) | [22.5](/filings/0001104659-25-105543.md) | [22.6](/filings/0001104659-26-054877.md) | [23.1](/filings/0001104659-26-093352.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 22,652,286 at 2026-08-06, from the cover of the [10-Q filed 2026-08-10](/filings/0001104659-26-093352.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:30 ET. No prices; not investment advice.